<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342041</url>
  </required_header>
  <id_info>
    <org_study_id>CTP13031H3</org_study_id>
    <nct_id>NCT02342041</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects</brief_title>
  <official_title>A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suven Life Sciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suven Life Sciences Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of
      SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single and multiple ascending dose study to assess the safety, tolerability and
      pharmacokinetics of SUVN-G3031 administered orally once a day to healthy male subjects. The
      study will be conducted under double-blind conditions.

      The primary objective is to evaluate the safety and tolerability of SUVN-G3031 following oral
      administration of single or multiple ascending doses and estimate the maximum tolerated dose
      of SUVN-G3031, if possible.

      The secondary objectives are to evaluate the single and repeat dose plasma pharmacokinetics
      following oral administration of single and multiple ascending doses of SUVN-G3031 in healthy
      male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single or multiple doses of SUVN-G3031 in healthy male subjects</measure>
    <time_frame>Range of Day 1-19</time_frame>
    <description>Safety variables - Adverse events, vital signs, electrocardiograms, telemetry, physical examination, and clinical laboratory assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the SUVN-G3031 plasma concentration-time curve in a dosing interval (AUC0-tau)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SUVN-G3031 plasma concentration-time curve from zero to infinity (AUC0-inf)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) and time of observation (tmax)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F), apparent volume of distribution (Vz/F), and elimination half life (t½)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index following multiple dosing of SUVN-G3031 (AI)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cognitive Disorders</condition>
  <arm_group>
    <arm_group_label>Single ascending dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of SUVN-G3031or placebo in healthy male subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of SUVN-G3031 or placebo in healthy male subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUVN-G3031</intervention_name>
    <arm_group_label>Single ascending dose</arm_group_label>
    <arm_group_label>Multiple ascending dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Single ascending dose</arm_group_label>
    <arm_group_label>Multiple ascending dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Healthy male aged 18 to 45 years with a BMI between 18 and 30 kg/m2, (inclusive).

        Exclusion Criteria:

          -  Standard exclusion criterion for Phase 1 clinical trial in healthy subjects.

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the volunteer at risk because of participation in the
             study, or influence the results or the volunteer's ability to participate

          -  History or presence of GI, hepatic, or renal disease or any other condition known to
             interfere with absorption, distribution, metabolism, or excretion of drugs as judged
             by Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murtaugh Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Medical Research Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SUVN-G3031</keyword>
  <keyword>histamine 3 (H3) receptor inverse agonist</keyword>
  <keyword>first in human</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>tolerability</keyword>
  <keyword>single dose</keyword>
  <keyword>repeat dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

